Takeda Pharmaceutical (TAK) Net Cash Flow Growth (1y) (2019 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 195.58% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -517.34% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -88.52% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 3,465.10% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 270.63% |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | -290.21% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -290.21% |
| Mar 31, 2026 | 116.17% |
| Dec 31, 2025 | 136.55% |
| Sep 30, 2025 | 858.34% |
| Jun 30, 2025 | -110.65% |
| Mar 31, 2025 | -160.72% |
| Dec 31, 2024 | -1,318.55% |
| Sep 30, 2024 | -80.77% |
| Jun 30, 2024 | 225.27% |
| Mar 31, 2024 | 140.21% |
| Dec 31, 2023 | 75.44% |
| Sep 30, 2023 | -31.00% |
| Jun 30, 2023 | 3.25% |
| Mar 31, 2023 | 8.54% |
| Dec 31, 2022 | -175.43% |
| Sep 30, 2022 | 1,230.72% |
| Jun 30, 2022 | 39.15% |
| Mar 31, 2022 | -1,170.42% |
| Dec 31, 2021 | 220.16% |
| Sep 30, 2021 | -403.13% |